Herceptin Approved For Early-Stage Adjuvant Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The average cost per course of therapy in the adjuvant indication is significantly more than for metastatic cancer.
You may also be interested in...
Herceptin Adjuvant Breast Cancer Sales Slow In First Quarter
Genentech eyes additional opportunities for trastuzumab in adjuvant setting in node-positive, hormone receptor-positive breast cancer patients.
Herceptin Adjuvant Breast Cancer Sales Slow In First Quarter
Genentech eyes additional opportunities for trastuzumab in adjuvant setting in node-positive, hormone receptor-positive breast cancer patients.
Pharmion Boosts Oncology Pipeline With Cabrellis Acquisition
Purchase gives Pharmion North American and EU rights to the novel anthracycline amrubicin, currently marketed in Japan for both small and non-small cell lung cancers.